🏛️ Verified NIH Record • Updated 2026-07-13
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL (NCT02717624)
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination With Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects With Mantle Cell Lymphoma
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Acerta Pharma BV
🩺 Plain-English Summary (8th-Grade Level)
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
Who can join: Review the eligibility criteria below.
Location: Research Site — Louisville, Kentucky
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Research Site — Louisville, Kentucky
- Research Site — Ann Arbor, Michigan
- Research Site — Hackensack, New Jersey
- Research Site — Morristown, New Jersey
- Research Site — Lake Success, New York
- Research Site — Columbus, Ohio
- Research Site — Nashville, Tennessee
- Research Site — Houston, Texas
- Research Site — Seattle, Washington
- Research Site — Seattle, Washington
- Research Site — Bologna,
- Research Site — Krakow,
- Research Site — Lodz,
- Research Site — Olsztyn,
- Research Site — Warsaw,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mantle Cell Lymphoma (MCL)
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma — Hackensack, New Jersey
- An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma — Tampa, Florida
- A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting — Milwaukee, Wisconsin
Explore by condition: All Mantle Cell Lymphoma (MCL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.